End-Point Interpretation in Clinical Trials: The Case for Discipline
- 28 February 1999
- journal article
- Published by Elsevier in Controlled Clinical Trials
- Vol. 20 (1) , 40-49
- https://doi.org/10.1016/s0197-2456(98)00051-8
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Carvedilol and the Food and Drug Administration (FDA) Approval Process: The FDA Paradigm and Reflections on Hypothesis TestingControlled Clinical Trials, 1999
- P-Value Interpretation and Alpha Allocation in Clinical TrialsAnnals of Epidemiology, 1998
- The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart FailureNew England Journal of Medicine, 1996
- Statistical issues in the regulation of medicinesStatistics in Medicine, 1995
- A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees.Circulation, 1994
- Beneficial effects of metoprolol in idiopathic dilated cardiomyopathyThe Lancet, 1993
- Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial InfarctionNew England Journal of Medicine, 1992
- Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart FailureNew England Journal of Medicine, 1991
- Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy.Heart, 1975